Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycaemic" glucose without numerically changing the incretin effect in patients with type 2 diabetes

被引：0
|
作者：
Foley, J. E. [1 ]
Becker, L. [2 ]
Koethe, L. [2 ]
Dejager, S. [3 ]
Schweizer, A. [4 ]
Nauck, M. A. [2 ]
机构：
[1] Novartis, E Hanover, NJ USA
[2] Diabet Zentrum, Bad Lauterberg Im Harz, Germany
[3] Novartis, Paris, France
[4] Novartis, Basel, Switzerland
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
917
引用
收藏
页码：S367 / S367
页数：1
相关论文
共 50 条
  • [1] Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as "Isoglycemic" Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
    Vardarli, Irfan
    Nauck, Michael A.
    Koethe, Lars D.
    Deacon, Carolyn F.
    Holst, Jens J.
    Schweizer, Anja
    Foley, James E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : 945 - 954
  • [2] Improved glucagon dynamics during hypoglycaemia and food-rechallenge by DPP-4 inhibition by vildagliptin in insulin-treated patients with type 2 diabetes
    Ahren, B.
    Farngren, J.
    Persson, M.
    Schweizer, A.
    Foley, J.
    DIABETOLOGIA, 2013, 56 : S51 - S52
  • [3] The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
    Bock, Gerlies
    Man, Chiara Dalla
    Micheletto, Francesco
    Basu, Rita
    Giesler, Paula D.
    Laugen, Jeanette
    Deacon, Carolyn F.
    Holst, Jens J.
    Toffolo, Gianna
    Cobelli, Claudio
    Rizza, Robert A.
    Vella, Adrian
    CLINICAL ENDOCRINOLOGY, 2010, 73 (02) : 189 - 196
  • [4] Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, vildagliptin, in Japanese patients with type 2 diabetes.
    Hayashi, N.
    Karube, M.
    Kumagai, Y.
    Fujita, Y.
    Irie, S.
    Ikeda, Y.
    He, Y. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S68 - S68
  • [5] Effect of a dipeptidyl peptidase 4 (DPP-4) inhibitor, vildagliptin, on gastrointestinal function, nutrient intake and glucose metabolism in type 2 diabetes
    Vella, A.
    Bock, G.
    Giesler, P. D.
    Burton, D. B.
    Foley, J. E.
    Rizza, R. A.
    Camilleri, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 (05): : 434 - 434
  • [6] Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin
    Forst, Thomas
    Bramlage, Peter
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (09) : 1299 - 1313
  • [7] Comparison of the novel Russian DPP-4 inhibitor gosogliptin with vildagliptin in patients with type 2 diabetes mellitus
    Galstyan, K. O.
    Nedosugova, L., V
    Petunina, N. A.
    Trakhtenberg, J. A.
    Vostokova, N. V.
    Karavaeva, O., V
    Chasovskaya, T. E.
    DIABETES MELLITUS, 2016, 19 (01): : 89 - 96
  • [8] Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes
    Man, Chiara Dalla
    Bock, Gerlies
    Giesler, Paula D.
    Serra, Denise B.
    Saylan, Monica Ligueros
    Foley, James E.
    Camilleri, Michael
    Toffolo, Gianna
    Cobelli, Claudio
    Rizza, Robert A.
    Vella, Adrian
    DIABETES CARE, 2009, 32 (01) : 14 - 18
  • [9] Improved meal-related insulin processing contributes to the enhancement of B-Cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
    Ahren, B.
    Pacini, G.
    Tura, A.
    Foley, J. E.
    Schweizer, A.
    HORMONE AND METABOLIC RESEARCH, 2007, 39 (11) : 826 - 829
  • [10] Vildagliptin: A novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes
    Ristic, Smiljana
    Bates, Peter C.
    DRUGS OF TODAY, 2006, 42 (08) : 519 - 531
12345